Interpreting ARANOTE: Darolutamide in Doublet and Triplet Therapy for Metastatic Castration-Sensitive Prostate Cancer
July 16th 2025
Panelists discuss how the ARANOTE trial’s progression-free survival benefits with darolutamide inform treatment selection between doublet and triplet approaches, emphasizing personalized decision-making based on tumor burden, patient performance status, and the “first shot, best shot” treatment philosophy.